Insider Selling: Heartflow (NASDAQ:HTFL) Insider Sells $987,052.30 in Stock

Posted by Francis Steltz on Sep 21st, 2026

Heartflow, Inc. (NASDAQ:HTFL – Get Free Report) insider Campbell Rogers sold 19,682 shares of the stock in a transaction on Friday, September 18th. The shares were sold at an average price of $50.15, for a total transaction of $987,052.30. Following the transaction, the insider owned 79,956 shares of the company’s stock, valued at $4,009,793.40. This trade represents a 19.75% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Campbell Rogers also recently made the following trade(s):

On Monday, August 17th, Campbell Rogers sold 9,219 shares of Heartflow stock. The stock was sold at an average price of $41.23, for a total transaction of $380,099.37.

Heartflow Price Performance

Shares of NASDAQ HTFL traded down $0.42 during mid-day trading on Monday, hitting $50.33. 1,379,826 shares of the company’s stock traded hands, compared to its average volume of 1,591,831. Heartflow, Inc. has a 1 year low of $20.13 and a 1 year high of $52.22. The company’s 50-day moving average is $37.75 and its two-hundred day moving average is $31.75. The company has a market capitalization of $4.38 billion and a P/E ratio of -27.50.

Heartflow (NASDAQ:HTFL – Get Free Report) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.15. Heartflow had a negative return on equity of 23.52% and a negative net margin of 55.82%.The company had revenue of $64.08 million for the quarter. Heartflow’s quarterly revenue was up 47.7% compared to the same quarter last year. Equities analysts anticipate that Heartflow, Inc. will post -0.75 EPS for the current fiscal year.

Hedge Funds Weigh In On Heartflow

A number of large investors have recently bought and sold shares of HTFL. Engineers Gate Manager LP bought a new position in Heartflow in the 2nd quarter valued at $590,000. Integrated Wealth Concepts LLC purchased a new stake in shares of Heartflow during the second quarter valued at $53,000. Squarepoint Ops LLC boosted its stake in shares of Heartflow by 72.0% during the second quarter. Squarepoint Ops LLC now owns 87,052 shares of the company’s stock valued at $2,554,000 after purchasing an additional 36,441 shares during the period. Arizona State Retirement System bought a new position in shares of Heartflow in the second quarter worth about $312,000. Finally, Allianz Asset Management GmbH purchased a new position in Heartflow in the 2nd quarter worth about $1,557,000.

Analyst Ratings Changes

A number of brokerages recently issued reports on HTFL. Robert W. Baird set a $45.00 price target on Heartflow in a research report on Friday, August 14th. Canaccord Genuity Group boosted their price objective on shares of Heartflow from $37.00 to $45.00 and gave the company a “buy” rating in a research report on Friday, August 14th. UBS Group initiated coverage on shares of Heartflow in a report on Wednesday, September 9th. They issued a “neutral” rating and a $55.00 target price for the company. Weiss Ratings raised shares of Heartflow from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, August 7th. Finally, Stifel Nicolaus upped their price target on shares of Heartflow from $40.00 to $45.00 and gave the company a “buy” rating in a report on Friday, August 14th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $44.88.

View Our Latest Report on HTFL

Heartflow Company Profile

(Get Free Report)

Heartflow, Inc is a medical technology company that develops artificial intelligence and imaging solutions for the diagnosis and management of coronary artery disease. Its platform analyzes data from coronary computed tomography angiography (CCTA) scans to create personalized, three-dimensional models of a patient’s coronary arteries.

The company’s primary offering, Heartflow Analysis, is designed to provide noninvasive estimates of fractional flow reserve derived from computed tomography (FFR^CT).